Concise Prescribing Info
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Mild heart failure 100-200 mg 2-3 times/day. Ophth Mydriasis As 2% soln: Instill as directed.
Oral: Severe heart failure, phaeochromocytoma. Ophthalmic: Angle-closure glaucoma.
Special Precautions
CV diseases; hyperthyroidism; DM; elderly; pregnancy, lactation; prostate disorders; occlusive vascular disease; cardiac arrhythmias.
Adverse Reactions
Palpitations, tachycardia, arrhythmias, reflex bradycardia. Hypotension, dizziness, fainting. Anxiety, fear, restlessness, insomnia, confusion, irritability, headache, psychotic symptoms. Dyspnoea, weakness, anorexia, nausea, vomiting. Mydriasis, difficulty in micturition and urinary retention, piloerection, sweating, increased salivation. Hyperglycaemia. Hypokalaemia and muscle tremor.
Drug Interactions
Increased cardiac effects with volatile anaesthetics, thyroid hormones, cardiac glycosides and antiarrhythmics. Additive hypotensive effects with antihypertensives. Severe hypotension may occur with guanethidine. Increased risk of hypotension and tachycardia with α-blockers. Increased risk of hypertension with nonselective β-beta blockers. Increased risk of hypertension and arrhythmias with TCAs. Additive CV toxicity with levodopa, bromocriptine.
ATC Classification
S01FB03 - ibopamine ; Belongs to the class of sympathomimetics used as mydriatics and cycloplegics.
C01CA16 - ibopamine ; Belongs to the class of adrenergic and dopaminergic cardiac stimulants excluding glycosides. Used in the treatment of heart failure.
Disclaimer: This information is independently developed by CIMS based on ibopamine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in